We aimed to assess the prognostic value of tumor infiltrating lymphocytes (TILs) in patients with bladder cancer (BC) after radical cystectomy (RC). We searched Pubmed, Web of Science and Scopus in April 2022 to identify studies assessing the prognostic value of TILs, including a subset of lymphocytes (eg, CD3, CD8, FOXP3), after RC. The endpoints were overall survival and recurrent free survival. Subgroup analyses were performed based on the evaluation method for TILs (ie, CD3, CD8, FOXP3, HE staining). Overall, 9 studies comprising 1413 patients were included in this meta-analysis. The meta-analysis revealed that elevated expressions of TILs were significantly associated with favorable OS (pooled hazard ratio [HR]: 0.65, 95% confidence interval [CI]: 0.51-0.83) and RFS (pooled HR: 0.48, 95% CI: 0.35-0.64). In subgroup analyses, high CD8+ TILs were also associated with favorable OS (HR: 0.51, 95% CI: 0.33-0.80) and RFS (pooled HR: 0.53, 95% CI: 0.36-0.76). Among 3 studies comprising 146 patients, high intratumoral TILs were significantly associated with favorable OS (pooled HR: 0.34, 95% CI: 0.19-0.60). TILs are useful prognostic markers in patients treated with RC for BC. Although the prognostic value of TILs is varied, depending on the subset and infiltration site, CD8+ TILs and intratumoral TILs are associated with oncologic outcomes. Further studies are warranted to explicate the predictive value of TILs on the response to perioperative systemic therapy to help clinical decision-making in patients with BC.

中文翻译：

---

膀胱癌根治性膀胱切除术后肿瘤浸润淋巴细胞的预后价值：系统评价和荟萃分析

我们的目的是评估肿瘤浸润淋巴细胞（TIL）对膀胱癌（BC）患者根治性膀胱切除术（RC）后的预后价值。我们于 2022 年 4 月检索了 Pubmed、Web of Science 和 Scopus，以确定评估 RC 后 TIL（包括淋巴细胞亚群（例如 CD3、CD8、FOXP3））预后价值的研究。终点是总生存期和无复发生存期。根据TIL的评估方法（即CD3、CD8、FOXP3、HE染色）进行亚组分析。总体而言，本次荟萃分析纳入了 9 项研究，涉及 1413 名患者。荟萃分析显示，TIL 表达升高与有利的 OS（汇总风险比 [HR]：0.65，95% 置信区间 [CI]：0.51-0.83）和 RFS（汇总 HR：0.48，95% CI： 0.35-0.64）。在亚组分析中，高 CD8+ TIL 还与良好的 OS（HR：0.51，95% CI：0.33-0.80）和 RFS（汇总 HR：0.53，95% CI：0.36-0.76）相关。在包含 146 名患者的 3 项研究中，高瘤内 TIL 与良好的 OS 显着相关（汇总 HR：0.34，95% CI：0.19-0.60）。对于接受 RC 治疗的 BC 患者，TIL 是有用的预后标志物。尽管 TIL 的预后价值各不相同，具体取决于子集和浸润部位，但 CD8+ TIL 和瘤内 TIL 与肿瘤学结果相关。需要进一步的研究来阐明 TIL 对围手术期全身治疗反应的预测价值，以帮助 BC 患者做出临床决策。